Day: September 5, 2024

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, held both virtually and in person at the Lotte New York Palace Hotel in New York City, September 9-11, 2024. Event Details Company Presentation:Date: Tuesday, September 10, 2024 Time: 8:00 – 8:30 a.m. Eastern Time (ET)Panel Participation:Topic: “Non-amyloid Approaches in Alzheimer’s Disease” Date: Tuesday, September 10, 2024 Time: 2:00 – 3:00 p.m. ETDuring the Company presentation, Dr. Maccecchini will provide...

Planegg/Martinsried, September 5, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its lead program MDG1015 for the treatment of advanced gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma in the phase 1 clinical trial (EPITOME1015-I) . EPITOME1015-I consists of a dose escalation followed by an expansion segment and aims to assess safety, feasibility and preliminary efficacy of MDG1015 in multiple solid tumor indications. “We are very excited to reach this milestone with our lead program MDG1015 which reinforces...

Strategic leadership change will drive further growth and expansion among core business units NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today announced the appoint of Ezra T. Ernst as Chief Executive Officer. Ernst succeeds Scott Milford, who will serve in a consultative role through the end of 2024. “Ezra brings the combination of operational and strategic excellence to the position, while also having a deep understanding of the company, the industry and key partners,” said XWELL Chairman of the Board, Bruce Bernstein. “This strategic leadership change will propel XWELL forward in its next phase. I trust that Ezra will deliver purpose-driven growth for XWELL through continued innovation and expansion, ultimately returning...

TransUnion’s Q3 2024 Credit Union Market Perspectives Report explores the current state of consumer credit and its impact on credit unions CHICAGO, Sept. 05, 2024 (GLOBE NEWSWIRE) — The newly released Q3 2024 Credit Union Market Perspectives Report from TransUnion (NYSE: TRU) found that balances continue to rise across all credit products, led by share growth among consumers in the super prime and subprime risk tiers. Among credit unions, balances grew among all consumer lending areas in Q2 2024. Growth ranged from 2.7% in credit union auto balances up to 14.4% for home equity loan balances as borrowers continue tapping into the equity in their home to make home improvements, consolidate other debt, or pay for other large purchases, like education expenses. Bankcards also saw significant YoY balance growth, up 8.6% over the period. “Despite...

BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest, will present at the H.C. Wainwright 26th Annual Global Investment Conference. The company presentation will be available for on-demand viewing Monday, September 9, 2024, at 7:00 a.m. ET on the investor section of the Tempest website at https://ir.tempesttx.com. About Tempest Therapeutics Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range...

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference. Presentation details are as follows: Event: H.C. Wainwright 26th Annual Global ConferenceDate: Monday, September 9, 2024Time: 7:00 am ET Webcast: https://journey.ct.events/view/f994d8d6-20e4-4670-8752-ee2696bcf2e6 Cidara’s presentation will be available on-demand from the above date/time in the investors section on the Company’s website at www.cidara.com. The replay...

TEL AVIV, Israel, Sept. 05, 2024 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace company focused on drone safety systems for defense and commercial drones and urban air mobility aircrafts, today announced that it has signed an agreement with BladeRanger Ltd. (TASE: BLRN) (“BladeRanger”), a developer of a powerful cleaning payload for drones that is designed for inspection and washing of solar panels and tall buildings. The multi-phase agreement is valued at approximately $230,000. As part of the agreement, ParaZero will support regulatory processes with the Israeli Civil Aviation Authority (CAA) to develop and certify a safe drone operating system for BladeRanger’s urban drones. This involves researching regulatory requirements, proposing potential solutions and...

Oslo, 5 September 2024 | Vow ASA (ticker OSE:VOW) today announces that its subsidiary Scanship AS has signed a FEED (Front End Engineering Design) contract with Murfitts Industries, the leading end of life tyre recycling company. The contract is the latest step in a programme which has seen the two companies co-operating on the development of a process to recover and re-use the raw materials from end of life tyres on a commercial scale. A major objective of the programme is to enable manufacturers to use the recovered material in the production of new tyres – helping to close the loop in a product lifecycle. The new FEED contract will result in the design and construction plans for a large scale pyrolysis plant, with the expectation that this will be operational in 2026. The plant will produce recovered Carbon Black (rCB), which will be...